knowledge -WSS

knowledge

author：knowledge 2025-09-29 18:18:24 - browse：7

A hand in pink glove holds a blue rack that contains three tubes of blood samples — first opinion coverage from STAT — Joe Raedle/Getty Images

During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the sites running the trials and the patients participating in them. Everyone from trial sponsors to the Food and Drug Administration has been quick to promise simpler processes, less hassle, and better experiences for everyone involved.

But look closer, and you’ll see that these grand promises often fall apart when sponsors implement complicated plans for collecting blood, tissue and other biospecimens and impossible processes for managing those samples. Behind all the talk and regulatory guidance, there’s a reluctance to change how these essential elements of clinical trial execution are handled, putting the very ideals that sponsors are trying to uphold at risk.

The concept of site and patient centricity frequently gets reduced to addressing only superficial gestures, such as committing to promptly paying sites for their work or using tablets for conducting patient surveys. But the essence of centricity extends far beyond these surface-level measures. It lies in addressing the unseen and unmentioned complexities of clinical trials and providing real solutions that focus on truly prioritizing the needs of trial sites and participants.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： FDA clears Verve to begin U.S. study of gene

WSS

Ukraine and a new approach to mental health in war

Ukraine and a new approach to mental health in war

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Roche acquires Telavant from Roivant, adding experimental IBD treatment

CDC's new outbreak response network to include Northeastern

Roche drug slashes death risk in early

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Thermo Fisher plant for manufacturing gene therapies to expand

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD podcast: Live from the 2023 STAT Summit

United colonoscopy coverage change 'may cost lives,' doctors say

FDA clears Verve to begin U.S. study of gene

Duchenne breakthrough therapy leaves behind pioneering families

What Congress can do to address the rural doctor shortage

State Dept. review finds Biden bears some blame for Afghanistan failures

CommonSpirit Health keeps growing, even as it loses money

hotspot

Drug for rare kidney disease narrowly misses mark in clinical trial

Roche acquires Telavant from Roivant, adding experimental IBD treatment

CZI to create biohub to build anti

Readout LOUD podcast: possible new ALS drug, artificial wombs

It's been 20 years since Dolly the sheep. Where's my clone?

Why a market frenzy over new weight loss drugs defies logic

hotspot

focus

entertainment

Wikipedia